FHTX - Foghorn Therapeutics Inc Stock Price, Fair Value and News

5.53USD-0.28 (-4.82%)Market Closed

Market Summary

USD5.53-0.28

Market Closed

-4.82%

FHTX Stock Price

View Fullscreen

FHTX RSI Chart

FHTX Valuation

Market Cap

235.5M

Price/Earnings (Trailing)

-2.53

Price/Sales (Trailing)

6.95

EV/EBITDA

-1.88

Price/Free Cashflow

-2.01

FHTX Price/Sales (Trailing)

FHTX Profitability

EBT Margin

-263.42%

Return on Equity

95.35%

Return on Assets

-36.45%

Free Cashflow Yield

-49.66%

FHTX Fundamentals

FHTX Revenue

Revenue (TTM)

33.9M

Rev. Growth (Yr)

-4.88%

Rev. Growth (Qtr)

-12.46%

FHTX Earnings

Earnings (TTM)

-93.0M

Earnings Growth (Yr)

17.95%

Earnings Growth (Qtr)

-3.77%

Breaking Down FHTX Revenue

Last 7 days

-0.5%

Last 30 days

-4.3%

Last 90 days

-15.2%

Trailing 12 Months

-15.3%

How does FHTX drawdown profile look like?

FHTX Financial Health

Current Ratio

4.06

FHTX Investor Care

Shares Dilution (1Y)

1.82%

Diluted EPS (TTM)

-2.2

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	33.9M	0	0	0
2023	20.6M	21.7M	32.6M	34.2M
2022	5.0M	9.2M	15.8M	19.2M
2021	652.3K	874.5K	1.1M	1.3M
2020	0	0	0	430.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Foghorn Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 11, 2024	cavalie fanny	sold	-72,133	6.5576	-11,000	chief strategy/bus ops officer
Aug 17, 2023	gottschalk adrian	gifted	-	-	-63,000	chief executive officer
Aug 17, 2023	gottschalk adrian	gifted	-	-	63,000	chief executive officer
Aug 16, 2023	agresta samuel	acquired	1,158,020	3.72	311,297	chief medical officer
Aug 16, 2023	agresta samuel	sold	-2,568,200	8.25	-311,297	chief medical officer
May 26, 2023	gottschalk adrian	gifted	-	-	-300,000	chief executive officer
Feb 17, 2023	gottschalk adrian	gifted	-	-	-4,371	chief executive officer
Feb 17, 2023	gottschalk adrian	gifted	-	-	4,371	chief executive officer
Feb 17, 2023	gottschalk adrian	sold	-	-	-184,939	chief executive officer
Oct 25, 2022	gottschalk adrian	acquired	-	-	4,371	chief executive officer

Which funds bought or sold FHTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	Artal Group S.A.	unchanged	-	187,031	4,836,030	0.12%
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-82,889	-	-%
May 16, 2024	Colony Group, LLC	new	-	632,000	632,000	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.91	-7,867	13,715	-%
May 15, 2024	BAKER BROS. ADVISORS LP	unchanged	-	11,707	302,131	-%
May 15, 2024	Driehaus Capital Management LLC	reduced	-18.43	-335,631	1,881,360	0.02%
May 15, 2024	STATE STREET CORP	added	3.56	210,761	2,936,720	-%
May 15, 2024	MORGAN STANLEY	reduced	-28.68	-174,930	503,049	-%
May 15, 2024	JACOBS LEVY EQUITY MANAGEMENT, INC	added	101	757,346	1,451,170	0.01%
May 15, 2024	HSBC HOLDINGS PLC	added	16.21	15,462	105,958	-%

Are Funds Buying or Selling FHTX?

Are funds buying FHTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own FHTX

No. of Funds

Unveiling Foghorn Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2022	fmr llc	-	0	SC 13G/A
Dec 13, 2021	eli lilly & co	9.7%	4e+06	SC 13G
Apr 19, 2021	kadoch cigall	11.05%	3,957,712	SC 13G
Feb 08, 2021	fmr llc	-	0	SC 13G
Feb 04, 2021	klarman family foundation	5.97%	2,139,639	SC 13G

Recent SEC filings of Foghorn Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 06, 2024	S-8	Employee Benefits Plan
May 06, 2024	8-K	Current Report
May 06, 2024	8-K	Current Report
May 06, 2024	10-Q	Quarterly Report
May 03, 2024	DEFA14A	DEFA14A
May 03, 2024	DEF 14A	DEF 14A
May 03, 2024	ARS	ARS
Apr 17, 2024	4	Insider Trading
Apr 17, 2024	3	Insider Trading
Apr 16, 2024	8-K	Current Report

Peers (Alternatives to Foghorn Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Foghorn Therapeutics Inc News

Latest updates

Foghorn Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Revenue	-12.5%	5,050,000	5,769,000	17,478,000	5,599,000	5,309,000	4,184,000	6,634,000	4,490,000	3,920,000	713,000	41,000	279,000	286,000	232,500	179,000
Operating Expenses	6.5%	33,244,000	31,227,000	34,559,000	37,649,000	38,626,000	36,070,000	34,893,000	33,678,000	31,724,000	28,795,000	26,302,000	23,540,000	23,416,000	21,030,000	18,668,000
S&GA Expenses	-100.0%	-	7,022,000	8,308,000	8,401,000	8,641,000	7,862,000	7,965,000	7,704,000	7,216,000	6,332,000	5,808,000	4,898,000	4,690,000	4,559,000	2,555,000
R&D Expenses	5.5%	25,534,000	24,205,000	26,251,000	29,248,000	29,985,000	28,208,000	26,928,000	25,974,000	24,508,000	22,463,000	20,494,000	18,642,000	18,726,000	16,471,000	16,113,000
EBITDA Margin	4.8%	-2.43	-2.55	-3.00	-5.05	-5.26	-5.49	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	236,000	499,000	495,000	486,000	321,000	202,000
Income Taxes	-100.0%	-	1,981,000	738,000	900,000	600,000	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-13.1%	-25,016,000	-22,120,000	-13,607,000	-28,545,000	-29,928,000	-28,886,000	-25,769,000	-27,313,000	-26,914,000	-	-	-	-	-	-
EBT Margin	4.5%	-2.63	-2.76	-3.10	-5.21	-5.43	-5.66	-	-	-	-	-	-	-	-	-
Net Income	-3.8%	-25,016,000	-24,106,000	-14,345,000	-29,487,000	-30,488,000	-28,886,000	-25,769,000	-27,313,000	-26,914,000	-29,143,000	-26,080,000	-23,111,000	-22,986,000	-20,758,000	-18,367,000
Net Income Margin	4.8%	-2.74	-2.88	-3.17	-5.28	-5.45	-5.66	-6.93	-11.94	-21.25	-76.82	-84.74	-97.45	-	-	-
Free Cashflow	-6.8%	-29,446,000	-27,578,000	-27,292,000	-32,644,000	-31,816,000	-29,193,000	-20,316,000	-29,376,000	271,287,000	11,802,000	-20,732,000	-19,692,000	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	-10.8%	255	286	313	340	373	405	434	457	488	520	186	209	230	256	142	22.00
Current Assets	-11.9%	212	240	265	290	321	351	378	400	430	460	124	145	165	191	78.00	17.00
Cash Equivalents	0.8%	81.00	80.00	70.00	58.00	51.00	52.00	88.00	61.00	214	103	58.00	125	66.00	95.00	75.00	17.00
Liabilities	-2.9%	352	363	371	389	397	405	410	409	416	423	105	104	105	109	99.00	24.00
Current Liabilities	-10.9%	52.00	58.00	52.00	57.00	56.00	55.00	55.00	48.00	48.00	49.00	19.00	16.00	16.00	19.00	21.00	13.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	20.00	20.00	20.00	20.00	9.00	11.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	20.00	9.00	11.00
Shareholder's Equity	-26.3%	-97.49	-77.19	-	-	-24.59	0.00	24.00	48.00	72.00	97.00	81.00	104	125	146	-	-
Retained Earnings	-5.3%	-496	-471	-447	-433	-403	-373	-344	-318	-291	-264	-235	-209	-185	-162	-142	-94.14
Additional Paid-In Capital	1.1%	400	395	392	386	382	377	373	369	365	361	316	313	311	309	9.00	6.00
Shares Outstanding	0.7%	43.00	42.00	42.00	42.00	42.00	42.00	42.00	42.00	41.00	41.00	37.00	37.00	-	-	-	-
Float	-	-	-	-	200	-	-	-	335	-	-	-	209	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Cashflow From Operations	-6.6%	-29,345	-27,541	-27,210	-32,175	-31,180	-28,924	-19,986	-29,012	271,534	11,882	-20,502	-18,483	-23,147	-10,655	2,726	-12,595	-10,762	-	-
Share Based Compensation	5.7%	3,224	3,051	4,094	4,470	4,572	3,781	3,802	3,509	3,244	-	2,370	2,042	1,888	1,078	877	489	517	-	443
Cashflow From Investing	-27.5%	27,095	37,385	38,426	39,134	29,505	-6,507	46,051	-124,457	-159,409	9,673	-47,328	77,089	-3,261	-100,220	-5,425	-2,248	-1,021	-	-
Cashflow From Financing	527.4%	1,167	186	1,387	103	102	16.00	333	1,030	384	21,740	505	111	62.00	128,509	40,754	47,963	247	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

FHTX Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Collaboration revenue	$ 5,050	$ 5,309
Operating expenses:
Research and development	25,534	29,985
General and administrative	7,710	8,641
Total operating expenses	33,244	38,626
Loss from operations	(28,194)	(33,317)
Other income, net:
Interest income	2,439	2,669
Other income, net	739	720
Total other income, net	3,178	3,389
Loss before income taxes	(25,016)	(29,928)
Provision for income taxes	0	(560)
Net loss	$ (25,016)	$ (30,488)
Net loss per share attributable to common stockholders—basic (in dollars per share)	$ (0.59)	$ (0.73)
Net loss per share attributable to common stockholders—diluted (in dollars per share)	$ (0.59)	$ (0.73)
Weighted average common shares outstanding—basic (in shares)	42,428,813	41,811,087
Weighted average common shares outstanding—diluted (in shares)	42,428,813	41,811,087
Comprehensive loss:
Net loss	$ (25,016)	$ (30,488)
Other comprehensive gain:
Unrealized gains on marketable securities	329	1,116
Total other comprehensive gain	329	1,116
Total comprehensive loss	$ (24,687)	$ (29,372)
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]	Collaboration Revenue [Member]	Collaboration Revenue [Member]

FHTX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 79,253	$ 80,336
Marketable securities	127,408	153,721
Prepaid expenses and other current assets	4,859	6,124
Total current assets	211,520	240,181
Property and equipment, net	12,187	12,956
Restricted cash	1,708	1,708
Other assets	1,052	1,115
Operating lease right-of-use assets	28,537	29,956
Total assets	255,004	285,916
Current liabilities:
Accounts payable	5,631	6,260
Accrued expenses and other current liabilities	6,265	9,108
Operating lease liabilities	8,668	8,518
Deferred revenue	31,501	34,550
Total current liabilities	52,065	58,436
Operating lease liabilities, net of current portion	34,311	36,555
Deferred revenue, net of current portion	266,114	268,115
Total liabilities	352,490	363,106
Commitments and contingencies (Note 9)
Stockholders’ deficit:
Preferred stock, $0.0001 par value; 25,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock, $0.0001 par value; 175,000,000 shares authorized at March 31, 2024 and December 31, 2023; 42,585,616 shares issued and outstanding at March 31, 2024 and 42,282,040 shares issued and outstanding at December 31, 2023	4	4
Additional paid-in capital	399,587	395,196
Accumulated other comprehensive loss	(497)	(826)
Accumulated deficit	(496,580)	(471,564)
Total stockholders’ deficit	(97,486)	(77,190)
Total liabilities and stockholders’ deficit	$ 255,004	$ 285,916

About Foghorn Therapeutics Inc

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Adrian H. B. Gottschalk
WEBSITE	https://foghorntx.com
INDUSTRY	Biotechnology
EMPLOYEES	161

Foghorn Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Foghorn Therapeutics Inc? What does FHTX stand for in stocks?

FHTX is the stock ticker symbol of Foghorn Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Foghorn Therapeutics Inc (FHTX)?

As of Fri May 17 2024, market cap of Foghorn Therapeutics Inc is 235.5 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FHTX stock?

You can check FHTX's fair value in chart for subscribers.

What is the fair value of FHTX stock?

You can check FHTX's fair value in chart for subscribers. The fair value of Foghorn Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Foghorn Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for FHTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Foghorn Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether FHTX is over valued or under valued. Whether Foghorn Therapeutics Inc is cheap or expensive depends on the assumptions which impact Foghorn Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FHTX.

What is Foghorn Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, FHTX's PE ratio (Price to Earnings) is -2.53 and Price to Sales (PS) ratio is 6.95. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FHTX PE ratio will change depending on the future growth rate expectations of investors.